SD Biosensor, Inc.announced the signing of a tripartite memorandum of understanding (MOU) for the research and development (R&D) of new products targeting extensively drug-resistant tuberculosis using its Point-of-Care (POC) molecular diagnostic platform
Roche announced it has obtained the CE mark for its new SARS-CoV-2 Rapid Antigen Test Nasal. The test will be available in countries accepting the CE mark by mid-February 2021.